ZIM Laboratories (NSE:ZIMLAB, BOM:541400) has received Marketing Authorization from Australia's Therapeutic Goods Administration (TGA) for its central nervous system product, Rizatriptan Benzoate Orally Disintegrating Films, according to a Monday filing.
The approval was granted through its Australian subsidiary, ZIMTAS and marks the company's first regulatory approval in Australia, the filing said.
Rizatriptan is used for the acute treatment of migraine in adults. The approval paves the way for the commercial launch of the drug in Australia, the company said in the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.